AI Science Tracker
EN

Regularized glioma expression score associates with survival across archived cohorts

Central South University · 29 Jun 2024 · medicine

Discovery

Regularized glioma expression score associates with survival across archived cohorts

Source check: Source checked. Not independent scientific confirmation.

Finding: A stepwise-Cox plus ridge model constructed from a supplied glioma expression signature was associated with survival across nine archived cohorts. The final model was selected using average validation-cohort performance, so those cohorts do not provide an untouched external test. The narrow result is a retrospective score–outcome association, not a verified treatment target or clinical-benefit claim.

Technology: Mime; stepwise Cox selection; ridge-regularized survival learning

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A fitted ridge survival model following feature selection supplies the patient score whose observed survival association is assessed; software availability and visualization alone are not the represented result.
Test and result
Mime compared 117 combinations across one development and eight additional glioma cohorts. The selected STRICOM score separated survival outcomes using cohort median scores, and adjusted analyses considered established clinical/molecular covariates.
Limitation / still unknown
All additional cohorts informed final model selection and model-ranking comparisons; performance can be optimistic. Risk cutoffs are cohort-specific. Input signatures and clinical cohorts are reused, not new randomized or prospective evidence. The SDC1 example includes previously reported biology and is not represented as a newly discovered causal mechanism. Operational perturbation procedures and supplementary experimental details were not reviewed.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11269309/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Exact primary front and selected computational/clinical Methods and corresponding high-level Results; operational laboratory protocols excluded from review.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.